File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/RHU.0000000000001590
- Scopus: eid_2-s2.0-85122308378
- PMID: 33105316
- WOS: WOS:000733569200022
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Conventional and Biologic Disease-Modifying Antirheumatic Drugs Are Not Associated With Increase in or Progression of Cervical Neoplasia Among Patients With Spondyloarthritis
Title | Conventional and Biologic Disease-Modifying Antirheumatic Drugs Are Not Associated With Increase in or Progression of Cervical Neoplasia Among Patients With Spondyloarthritis |
---|---|
Authors | |
Keywords | spondyloarthritis cervical cancer antirheumatic agents risk incidence |
Issue Date | 2020 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://journals.lww.com/jclinrheum/pages/default.aspx |
Citation | JCR: Journal of Clinical Rheumatology, 2020, Epub 2020-10-22 How to Cite? |
Abstract | Objectives:
Using a centralized electronic database, we investigated the risk of cervical neoplasia (CN) and progression of cervical intraepithelial neoplasia (CIN) among patients with spondyloarthritis (SpA) receiving disease-modifying antirheumatic drugs (DMARDs).
Method:
A total of 951 patients with SpA were reviewed. Incidence and progression of CN and clinical data including age, ethnicity, smoking and drinking status, dates of first and last follow-up, history of psoriasis, inflammatory bowel disease, medications used, mean dose and duration of medications, and comorbidities were reviewed. Cox regression models were used to evaluate the individual risk of DMARDs with CN and the risk of CIN progression.
Results:
During a mean follow-up duration of 9.2 ± 5.9 years, 34 patients had developed CN, which translates to an incidence for development of CN in patients with SpA of 3.9 per 1000 patient-years. Univariate Cox regression analyses showed no differences in clinical characteristics (psoriasis hazards ratio [HR] = 0.92, p = 0.82; inflammatory bowel disease HR = 0.05, p = 0.61; diabetes mellitus HR = 2.82, p = 0.21; chronic kidney disease HR = 0.39, p = 0.35) and medications exposure (sulfasalazine HR = 0.49, p = 0.30; methotrexate HR = 0.52, p = 0.11; leflunomide HR = 0.52, p = 0.37; adalimumab HR = 0.83, p = 0.80; certolizumab HR = 0.05, p = 0.74; etanercept HR = 0.40, p = 0.36; golimumab HR = 0.05, p = 0.32; infliximab HR = 0.05, p = 0.39; secukinumab HR = 1.00, p = 1.00; ustekinumab HR = 0.05, p = 0.78) between patients who had and had not develop CN during the study period. Progression of CIN was independently associated with higher grades of CIN lesion (HR = 6.20; p = 0.05).
Conclusions:
There was low risk of development and progression of CN in patients with SpA on conventional or biologic DMARD therapy. |
Persistent Identifier | http://hdl.handle.net/10722/290945 |
ISSN | 2023 Impact Factor: 2.4 2023 SCImago Journal Rankings: 0.539 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, PH | - |
dc.contributor.author | Chan, SCW | - |
dc.contributor.author | Lau, CS | - |
dc.contributor.author | Seto, MTY | - |
dc.contributor.author | Chung, HY | - |
dc.date.accessioned | 2020-11-02T05:49:20Z | - |
dc.date.available | 2020-11-02T05:49:20Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | JCR: Journal of Clinical Rheumatology, 2020, Epub 2020-10-22 | - |
dc.identifier.issn | 1076-1608 | - |
dc.identifier.uri | http://hdl.handle.net/10722/290945 | - |
dc.description.abstract | Objectives: Using a centralized electronic database, we investigated the risk of cervical neoplasia (CN) and progression of cervical intraepithelial neoplasia (CIN) among patients with spondyloarthritis (SpA) receiving disease-modifying antirheumatic drugs (DMARDs). Method: A total of 951 patients with SpA were reviewed. Incidence and progression of CN and clinical data including age, ethnicity, smoking and drinking status, dates of first and last follow-up, history of psoriasis, inflammatory bowel disease, medications used, mean dose and duration of medications, and comorbidities were reviewed. Cox regression models were used to evaluate the individual risk of DMARDs with CN and the risk of CIN progression. Results: During a mean follow-up duration of 9.2 ± 5.9 years, 34 patients had developed CN, which translates to an incidence for development of CN in patients with SpA of 3.9 per 1000 patient-years. Univariate Cox regression analyses showed no differences in clinical characteristics (psoriasis hazards ratio [HR] = 0.92, p = 0.82; inflammatory bowel disease HR = 0.05, p = 0.61; diabetes mellitus HR = 2.82, p = 0.21; chronic kidney disease HR = 0.39, p = 0.35) and medications exposure (sulfasalazine HR = 0.49, p = 0.30; methotrexate HR = 0.52, p = 0.11; leflunomide HR = 0.52, p = 0.37; adalimumab HR = 0.83, p = 0.80; certolizumab HR = 0.05, p = 0.74; etanercept HR = 0.40, p = 0.36; golimumab HR = 0.05, p = 0.32; infliximab HR = 0.05, p = 0.39; secukinumab HR = 1.00, p = 1.00; ustekinumab HR = 0.05, p = 0.78) between patients who had and had not develop CN during the study period. Progression of CIN was independently associated with higher grades of CIN lesion (HR = 6.20; p = 0.05). Conclusions: There was low risk of development and progression of CN in patients with SpA on conventional or biologic DMARD therapy. | - |
dc.language | eng | - |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://journals.lww.com/jclinrheum/pages/default.aspx | - |
dc.relation.ispartof | JCR: Journal of Clinical Rheumatology | - |
dc.rights | This is a non-final version of an article published in final form in (provide complete journal citation) | - |
dc.subject | spondyloarthritis | - |
dc.subject | cervical cancer | - |
dc.subject | antirheumatic agents | - |
dc.subject | risk | - |
dc.subject | incidence | - |
dc.title | Conventional and Biologic Disease-Modifying Antirheumatic Drugs Are Not Associated With Increase in or Progression of Cervical Neoplasia Among Patients With Spondyloarthritis | - |
dc.type | Article | - |
dc.identifier.email | Li, PH: liphilip@hku.hk | - |
dc.identifier.email | Lau, CS: cslau@hku.hk | - |
dc.identifier.email | Chung, HY: jameschy@hku.hk | - |
dc.identifier.authority | Li, PH=rp02669 | - |
dc.identifier.authority | Lau, CS=rp01348 | - |
dc.identifier.authority | Chung, HY=rp02330 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1097/RHU.0000000000001590 | - |
dc.identifier.pmid | 33105316 | - |
dc.identifier.scopus | eid_2-s2.0-85122308378 | - |
dc.identifier.hkuros | 318484 | - |
dc.identifier.volume | Epub 2020-10-22 | - |
dc.identifier.isi | WOS:000733569200022 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1076-1608 | - |